Merck hope to develop biologic drug conjugates using Ambrx’s “site-specific protein medicinal chemistry technology”
Merck is paying an upfront fee of $15 million and is eligible to receive milestones totalling up to $288 million. Ambrx will also receive royalties.
Richard Murray, head of biologics and vaccines research at Merck said that this collaboration will allow us to combine Ambrx’s expertise in site-specific protein conjugation chemistry with Merck’s expanding antibody capabilities and extensive small molecule resources.
Follow us on Twitter @CKScienceJobs to receive more industry news and CK jobs of the week updates
Tags: Ambrx, Biotech, chemicals, chemistry technology, CK Science, Clinical jobs, engineering jobs, graduate science jobs uk, jobs in science, medical devices, Merck & Co, Pharmaceutical, PharmaTimes, recruitment agencies, science, science jobs, science jobs uk, science news, science recruitment, scientific job agencies, scientific jobs, scientific recruitment agencies uk, scientific recruitment uk, Therapeutics